子宫浆液性乳头状癌患者的预后因素及治疗相关结局

Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma.

作者信息

Sagr Emad R, Denschlag Dominik, Kerim-Dikeni Abbas, Stanimir Gerald, Gitsch Gerald, Gilbert Lucy

机构信息

Division of Gynecological Oncology, Department of Obstetrics and Gynecology, McGill University, Montreal, Canada.

出版信息

Anticancer Res. 2007 Mar-Apr;27(2):1213-7.

PMID:17465265

Abstract

UNLABELLED

A retrospective analysis was performed in order to evaluate prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma (UPSC).

PATIENTS AND METHODS

Between 1989 and 2003 forty-five patients with UPSC were treated at the McGill University Health Centre (MUHC), and therefore were included in the analysis. Age, race, history, tumor stage and grade, invasion and metastasis, treatment and outcome for each patient were evaluated.

RESULTS

According to FIGO classification, Stage I, II, III, and IV tumors were identified in 36%, 9%, 44%, and 11% of the patients, respectively. At the time of analysis, 37.8% of patients (17/45) were dead due to disease, with a mean survival of 22 months (SD +/- 7.5 months). Cause-specific survival for the entire group was 69%, 66%, and 58% at 2, 3, and 5 years, respectively. With respect to disease stage, 5-year cause-specific survival for stage I, II, III, and IV was 100%, 75%, 43%, and 0%, respectively. Univariate analysis comparing cause-specific survival curves demonstrated a statistically significant difference for disease stage (p < 0.0001) and depth of myometrial invasion (p = 0.008). However, in multivariate analysis, only disease stage had a significant impact on cause-specific survival (p < 0.01).

CONCLUSION

Disease stage is the only independent significant prognostic factor regarding cause-specific survival in patients with UPSC.

摘要

未标注

进行了一项回顾性分析，以评估子宫浆液性乳头状癌（UPSC）患者的预后因素和治疗相关结果。

患者与方法

1989年至2003年间，麦吉尔大学健康中心（MUHC）共治疗了45例UPSC患者，因此将其纳入分析。评估了每位患者的年龄、种族、病史、肿瘤分期和分级、浸润和转移情况、治疗及结果。

结果

根据国际妇产科联盟（FIGO）分类，分别在36%、9%、44%和11%的患者中发现了I期、II期、III期和IV期肿瘤。在分析时，37.8%的患者（17/45）因疾病死亡，平均生存期为22个月（标准差±7.5个月）。整个组的特定病因生存率在2年、3年和5年时分别为69%、66%和58%。就疾病分期而言，I期、II期、III期和IV期的5年特定病因生存率分别为100%、75%、43%和0%。比较特定病因生存曲线的单因素分析显示，疾病分期（p < 0.0001）和肌层浸润深度（p = 0.008）存在统计学显著差异。然而，在多因素分析中，只有疾病分期对特定病因生存有显著影响（p < 0.01）。